GNPX News and Press, Genprex Inc. From 07/30/20

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its Chairman and Chief Executive Officer, Rodney Varne...

Boxlight (NASDAQ: BOXL )   -27%  after  pricing  equity offering. More news on: Boxlight Corporation, Global Eagle Entertainment Inc., Sypris Solutions, Inc., Stocks on the move, , Read more ...

Modern-day mobile technology is making strides in the medical device industry and is opening up new avenues for both physicians and patients. However, for these devices to be successful, they need approval from the FDA. Initially, mobile technology was only referred to as the device that was i...

Since the outbreak of COVID-19, a lot of industries have come to a standstill and most institutions and research centers have scrambled to look for ways to control and curb this deadly pandemic. Interestingly, the pandemic has also brought a lot of regrets to some inventors. The regret comes a...

You may have heard about machine learning and data science in different aspects of life, such as in how your insurance premiums are determined. But, did you know that machine learning and data science are playing an increasing role in public health? Read on and learn about this exciting develo...

July 22, 2020 Palm Beach, FL – July 22, 2020  – The rising incidence of liver cancer and growing research activities for developing novel treatments plus the availability of newer drugs and treatments coupled with rising awareness among consumer/patients regardi...

Awarded an NIH Grant. Yesterday, Genprex (GNPX) announced that a grant of $2.59 million awarded to the company by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. This grant will fund the ongoing preclinical research for proof-of-principle...

Genprex (NASDAQ: GNPX) , today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the company’s potentially curative diabetes gene therapy, was awarded a grant of $2.59 million from the National Institutes of Health (“NIH&...

Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developin...

It is crystal clear that clinical trials are the surest way to bring new drugs into the market. While most clinical trials are costly, nine out of ten drugs in clinical development are never approved. Most of these treatments fail in clinical trials due to a lack of the desired effect, and som...